What are the commercial determinants of cancer control policy? Launch of Eurohealth special edition and webinar discussion

27 April 2022, 12:00 – 13:00 Central European Summer Time (virtual event)

Cancer is a major health, social and public policy challenge and successfully tackling it requires an understanding of all its determinants. Although commercial determinants are a relatively new field of study, there are emerging themes which are very important for cancer policy along the cancer control continuum.

Commercial determinants are those private-sector activities that affect the health of populations. They can have a negative impact, as commercial interests can trump nobler health goals.

So, how do commercial determinants affect cancer control policies in Europe? What are the challenges and opportunities for governing them along the cancer control continuum? Join our webinar to learn more.

Prevalence of cancer in the European region

Cancer is responsible for a high burden of disease within the WHO European Region. In 2020 alone, 4.8 million people in the region were diagnosed with cancer, of whom a staggering 2.2 million people lost their lives.

By 2030, these numbers are estimated to reach 5.4 million new diagnoses annually and 2.5 million deaths each year. Additionally, these numbers will most likely be an underestimate given the impact of the COVID-19 pandemic on delayed diagnosis and treatments. If efficient prevention and early detection strategies are in place, 30-40% of cancers are preventable. This is not being achieved due to cancer policy-making remaining quite far from what evidence and cost-effectiveness recommends, with treatment often being prioritized over prevention and early detection strategies, for example.

Cancer policy-making also differs significantly across the European Region, contributing to the widening of health inequalities within and between countries. Action on cancer prevention and control is a key priority to curb the burden of disease within the population of the European Region and to achieve the Sustainable Development Goal target to reduce by one third premature mortality from noncommunicable diseases by 2030.

keynote speakers

  • Marilys Corbex, WHO Regional Office for Europe
  • Monika Kosinska, WHO headquarters

speaker

  • Gauden Galea, WHO Representative Office in China
  • Stuart Hogarth, University of Cambridge, UK
  • Richard Sullivan, King’s College London, United Kingdom

moderators

  • Matthias Wismar and Erica Richardson, European Observatory on Health Systems and Policies

This event is intended for policy-makers, advisors, national experts, medical and health-care professionals, members of professional societies, researchers, advocates and representatives of nongovernmental organizations.

Leave a Comment